BACKGROUND: Percutaneous interventions for chronic total occlusions have low success rates, primarily because of failure of guide wire crossing. Collagen-rich matrix constitutes the main barrier to chronic total occlusion crossing. In preclinical studies, local delivery of a bacterial collagenase formulation improved guide wire crossing. The Collagenase Total Occlusion-1 (CTO-1) Trial is a phase I, dose-escalation trial to assess the safety and efficacy of collagenase therapy to facilitate guide wire crossing in coronary artery chronic occlusions. METHODS AND RESULTS: Twenty subjects with ≥1 previous failure of chronic total occlusion guide wire crossing were enrolled at 2 sites. Subjects were treated in 4 distinct cohorts of 5 patients, with escalation of collagenase dose in each cohort from 300 to 1200 μg. Collagenase was locally delivered into the occlusions with either an over-the-wire balloon system (n=8) or a fine-cross microcatheter (n=12) for a period of 30 minutes. Subjects were brought back to the catheterization laboratory for guide wire crossing and angioplasty the next day. Guide wire crossing was successfully achieved in 15 subjects (75%). A soft-tip guide wire (Whisper, Pilot-50, Fielder XT) was either the sole or predominant guide wire used in 75% of successful crossings. Non-ST-segment-elevation myocardial infarctions occurred in 3 patients as a result of side-branch ischemia during stenting. Computed tomographic angiography at 3 months showed no late complications and patent stents in successfully treated chronic total occlusion. Anginal improvement occurred with a reduction in Canadian Cardiovascular Society class from baseline to 3 months (2.5±0.6 versus 0.9±0.9; P<0.001). CONCLUSION: Local delivery of collagenase into coronary chronic total occlusion is feasible and safe with encouraging guide wire crossing results in previously failed cases. Larger clinical trials are required to determine efficacy. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01271335.
BACKGROUND: Percutaneous interventions for chronic total occlusions have low success rates, primarily because of failure of guide wire crossing. Collagen-rich matrix constitutes the main barrier to chronic total occlusion crossing. In preclinical studies, local delivery of a bacterial collagenase formulation improved guide wire crossing. The Collagenase Total Occlusion-1 (CTO-1) Trial is a phase I, dose-escalation trial to assess the safety and efficacy of collagenase therapy to facilitate guide wire crossing in coronary artery chronic occlusions. METHODS AND RESULTS: Twenty subjects with ≥1 previous failure of chronic total occlusion guide wire crossing were enrolled at 2 sites. Subjects were treated in 4 distinct cohorts of 5 patients, with escalation of collagenase dose in each cohort from 300 to 1200 μg. Collagenase was locally delivered into the occlusions with either an over-the-wire balloon system (n=8) or a fine-cross microcatheter (n=12) for a period of 30 minutes. Subjects were brought back to the catheterization laboratory for guide wire crossing and angioplasty the next day. Guide wire crossing was successfully achieved in 15 subjects (75%). A soft-tip guide wire (Whisper, Pilot-50, Fielder XT) was either the sole or predominant guide wire used in 75% of successful crossings. Non-ST-segment-elevation myocardial infarctions occurred in 3 patients as a result of side-branch ischemia during stenting. Computed tomographic angiography at 3 months showed no late complications and patent stents in successfully treated chronic total occlusion. Anginal improvement occurred with a reduction in Canadian Cardiovascular Society class from baseline to 3 months (2.5±0.6 versus 0.9±0.9; P<0.001). CONCLUSION: Local delivery of collagenase into coronary chronic total occlusion is feasible and safe with encouraging guide wire crossing results in previously failed cases. Larger clinical trials are required to determine efficacy. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01271335.
Authors: Nigel R Munce; Victor X D Yang; Beau A Standish; Beiping Qiang; Jagdish Butany; Brian K Courtney; John J Graham; Alexander J Dick; Bradley H Strauss; Graham A Wright; I Alex Vitkin Journal: Lasers Surg Med Date: 2007-01 Impact factor: 4.025
Authors: J Aaron Grantham; Steven P Marso; John Spertus; John House; David R Holmes; Barry D Rutherford Journal: JACC Cardiovasc Interv Date: 2009-06 Impact factor: 11.195
Authors: Craig A Thompson; John E Jayne; John F Robb; Bruce J Friedman; Aaron V Kaplan; Bruce D Hettleman; Nathaniel W Niles; William L Lombardi Journal: JACC Cardiovasc Interv Date: 2009-09 Impact factor: 11.195
Authors: Alfredo R Galassi; Salvatore D Tomasello; Nicolaus Reifart; Gerald S Werner; George Sianos; Hans Bonnier; Horst Sievert; Stephan Ehladad; Alexander Bufe; Joachim Shofer; Anthony Gershlick; David Hildick-Smith; Javier Escaned; Andrejs Erglis; Imad Sheiban; Leif Thuesen; Anthony Serra; Evald Christiansen; Achim Buettner; Luca Costanzo; Giombattista Barrano; Carlo Di Mario Journal: EuroIntervention Date: 2011-08 Impact factor: 6.534
Authors: Ronen Jaffe; General Leung; Nigel R Munce; Amandeep S Thind; Howard Leong-Poi; Kevan J T Anderson; Xiuling Qi; Judy Trogadis; Ariella Nadler; Davida Shiff; Jamie Saperia; Julia Lockwood; Chaim Jacobs; Beiping Qiang; Aaron Teitelbaum; Alexander J Dick; John D Sparkes; Jagdish Butany; Graham A Wright; Bradley H Strauss Journal: J Am Coll Cardiol Date: 2009-03-31 Impact factor: 24.094
Authors: David E Kandzari; Sunil V Rao; Jeffrey W Moses; Vladimir Dzavik; Bradley H Strauss; Michael J Kutryk; Charles A Simonton; Jyotsna Garg; Yuliya Lokhnygina; G B John Mancini; Eunice Yeoh; Christopher E Buller Journal: JACC Cardiovasc Interv Date: 2009-02 Impact factor: 11.195
Authors: Lawrence C Hurst; Marie A Badalamente; Vincent R Hentz; Robert N Hotchkiss; F Thomas D Kaplan; Roy A Meals; Theodore M Smith; John Rodzvilla Journal: N Engl J Med Date: 2009-09-03 Impact factor: 91.245
Authors: Loes P Hoebers; Bimmer E Claessen; George D Dangas; Truls Råmunddal; Roxana Mehran; José P S Henriques Journal: Nat Rev Cardiol Date: 2014-05-27 Impact factor: 32.419